Israel’s ImPact Biotech has received Orphan treatment designation from the US FDA for its Padeliporfin VTP in Pancreatic Cancer. ImPact stands for IMmune Photo Activated Cancer Treatment and VTP is Vascular Targeted Photodynamic therapy.
Light-activated cancer treatment gets US support
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.